[Burden of disease and risk factors among children under 5 years in China from 1990 to 2019: a perspective of international comparison]

Based on the Global Burden of Disease study 2019, the standardized mortality rate and disability-adjusted life years (DALYs) rate of children under 5 years old were selected as evaluation indicators to compare and analyze the current situation and differences of disease burden of children under 5 years old between China and other regions from 1990 to 2019. The change trend and difference of disease burden of children under 5 years old in China were analyzed by sexes. From 1990 to 2019, the all-cause standardized mortality rate of children under 5 years old in China decreased from 1 153.81/100 000 to 160.39/100 000, and the all-cause standardized DALY rate decreased from 104 426.40/100 000 to 16 479.01/100 000. In 2019, neonatal preterm birth, congenital heart anomalies and lower respiratory infections ranked the top three disease burden of children under 5 years old in China. Except that the disease burden of neonatal preterm birth was lower than that in North America, they were much higher than that in Western Europe and North America in the same period. The burden of unintentional injury diseases, including pulmonary aspiration and foreign body in airway and drowning, was higher than that in Western Europe and North America. The standardized mortality and DALY rate of the top ten diseases and injuries in boys and girls under 5 years old in China showed a downward trend (P<0.05), and most of them were higher in boys than girls (P<0.05). From 1990 to 2019, the disease burden of children under 5 years old in China decreased significantly. However, compared other regions, it is still necessary to strengthen the prevention and control of neonatal premature birth, birth defects and unintentional injuries, and take different sex-specific interventions to improve the overall health of children.

Imaging of dopamine transporters with technetium-99m TRODAT-1 and single photon emission computed tomography

The authors wanted to evaluate the usefulness of 99Tcm-TRODAT-1 as an imaging agent for measuring changes in dopamine transporter concentrations in Parkinson disease (PD) and correlate the findings to the severity of the disease as measured by the Hoehn and Yahr scale (H/Y). Twenty-two healthy volunteers and 27 patients with PD of H/Y stage I-IV were evaluated. Acquisitions were performed 2 hours after injection of 99Tcm-TRODAT-1. Regions of interest were drawn over the striatum and the cerebellum, and the ratios of striatum-to-cerebellum (ST/CB) were calculated. Patients with PD showed a significant decrease in the striatal uptake of 99Tcm-TRODAT-1 compared to healthy volunteers, and the ST/CB ratios were closely related to the stage of PD. The present study demonstrates that it is possible to visualize and quantify changes in dopamine transporter in the striatum of patients with PD using 99Tcm-TRODAT-1 and SPECT with good correlation to H/Y stage and unified Parkinson's disease rating scale (UPDRS) scale.

Expression of p16INK4 and retinoblastoma protein Rb in vulvar lesions of Chinese women

The protein products of the two tumor suppressor genes located on 9p and 13p, p16INK4 and Rb, respectively, play an important role in regulation of the cell cycle and are implicated in tumorigenesis. We examined 49 cases of benign vulvar lesions, vulvar intraepithelial neoplasia (VIN), and squamous cell carcinoma with immunohistochemical staining to determine expression of p16INK4 and Rb. All and 86% of benign lesions expressed Rb and p16INK4, respectively; 40% each of VIN I and VIN III expressed p16INK4 and Rb, respectively; and 37 and 68% of squamous cell carcinomas expressed p16INK4 and Rb, respectively. The combination of the lack of p16INK4 and/or Rb expression increased from benign lesions (14.3%), through VIN I (60%) and VIN III (60%), to invasive squamous cell carcinoma (72%), thus supporting the postulation that alterations in p16INK4 or Rb could be significant events in progression of disease. The loss of Rb expression also increased from stage I carcinoma (16.7%) through stage II (26.7%) and III (44.4%), to IV (50%), suggesting that Rb may play an important role in tumor progression. A larger study on VIN lesions and genetic coding is suggested to further investigate the role of p16INK4, Rb, and other factors in tumorigenesis and progression of vulvar cancers.